NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell...
SANTA ANA, Calif., June 3, 2024 – NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative...
View ArticleNKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell...
SANTA ANA, Calif., June 12, 2024 – NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative...
View ArticleNKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
SANTA ANA, Calif., July 15, 2024 — NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative...
View ArticleNKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at...
SANTA ANA, Calif., July 18, 2024 — NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative...
View ArticleNKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024...
SNK01, a cryopreserved autologous non-genetically modified NK cell product, is able to effectively reduce α-synuclein (α-syn) protein levels in the cerebral spinal fluid (CSF) of Alzheimer’s patients;...
View ArticleNKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment...
SANTA ANA, Calif., September 3, 2024 — NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of...
View ArticleNKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s...
Two of the first three patients in the Phase 1 cohort of the Phase 1/2a clinical trial, treated at the highest dose of 6 billion cells per treatment, were found to have improved CDR-SB cognitive...
View ArticleNKGen Biotech Announces Poster Presentations at the 17th Annual Clinical...
SANTA ANA, Calif., October 8, 2024 — NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative...
View ArticleNKGen Biotech Announces Upcoming Presentation at the 16th World Stroke...
SANTA ANA, Calif., October 15, 2024 — NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative...
View ArticleNKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at...
Newly analyzed biomarker data from the initial dose-escalation Phase 1 AD trial found that troculeucel reduces GFAP, NfL, p-tau181, GDF-15, and LTBP2 levels, which are detectable up to 10 years before...
View Article